Analyst Reco. Cybin Inc.

Equities

CLXPF

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2025-07-18 pm EDT			5-day change	1st Jan Change
8.320 ^USD	-1.65%		+8.90%	-5.67%

Jul. 17	Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder	CI
Jul. 17	Cybin Says UK Regulator Approves Start of Second Phase 3 Trial for Experimental Adjunctive Treatment for Major Depressive Disorder	MT

Analyst Reco.

HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating	23-11-17	MT
Oppenheimer Adjusts Cybin Price Target to $4 From $4.50, Maintains Outperform Rating	23-08-15	MT
Canaccord Genuity Adjusts Price Target on Cybin to $5 From $6, Maintains Buy Rating	23-08-11	MT
Stifel Nicolaus Adjusts Cybin's Price Target to $1.13 From $1.10, Maintains Speculative Buy Rating	23-07-03	MT
Canaccord Genuity Trims Price Target on Cybin to $6 From $7, Maintains Buy Rating	23-07-03	MT
EF Hutton Initiates Cybin at Buy With $3 Price Target	22-12-16	MT
Stifel Nicolaus Adjusts Cybin Price Target to CA$3 From CA$8.25, Maintains Speculative Buy Rating	22-08-24	MT
Stifel Nicolaus Adjusts Cybin PT to CA$8.25 From CA$10, Maintains Speculative Buy Rating	21-11-23	MT
HC Wainwright Adjusts Cybin's Price Target to $10 From $8, Reiterates Buy Rating	21-11-22	MT
CYBIN : Oppenheimer Initiates Coverage on Cybin With Outperform Rating, $7 Price Target	21-10-05	MT
CYBIN : Canaccord Genuity Adjusts Cybin's Price Target to $7 From $6, Reiterates Buy Rating	21-08-27	MT
CYBIN : Cantor Fitzgerald Starts Cybin at Overweight with $9 Price Target	21-08-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock markets for all

100% Free Registration

100% Free Registration